Angiotensin‐Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.047533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Wonse Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematical Sciences, RIMS, and AIIS Seoul National University Seoul Republic of Korea. Hauptthemen laut MEDLINE: Heart Failure, Aminobutyrates, Neprilysin, Glomerular Filtration Rate. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sacubitril/valsartan is known to reduce adverse renal outcomes and slow the decline in estimated glomerular filtration rate (eGFR) compared with renin‐angiotensin system (RAS) inhibitors across the entire spectrum of heart failure. However, whether these renoprotective effects differ by sex has not been elucidated. Thus, we aimed to evaluate whether the treatment effect of sacubitril/valsartan versus RAS inhibitors on renal outcomes differs by sex.
Methods
Data sets from the PARADIGM‐HF (Prospective Comparison of Angiotensin Receptor‐Neprilysin Inhibitor With Angiotensin‐Converting Enzyme Inhibition to Determine Impact on Global Mortality and Morbidity in Heart Failure; ejection fraction ≤40%, n=8399) and PARAGON‐HF (Prospective Comparison of Angiotensin Receptor‐Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction; ejection fraction ≥45%, n=4796) trials were integrated in a prespecified pooled analysis. We evaluated the treatment effect (sacubitril/valsartan versus RAS inhibitors) on the prespecified renal composite outcome (death from renal failure, end‐stage renal disease, or ≥50% reduction in eGFR) and changes in eGFR slope in female (n=4311) and male (n=8884) patients to determine whether sex modified the effect of sacubitril/valsartan on renal outcomes.
Results
At baseline, women exhibited lower eGFR values than men (67.2±19.7 versus 72.6±20.4 mL/min/1.73 m 2 , P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mathematical Sciences, RIMS, and AIIS Seoul National University Seoul Republic of Korea.
- MetaEyes Seoul Republic of Korea.
- Cardiovascular Center, Division of Cardiology, Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of Korea.
- Cardiology Department University of California San Diego La Jolla CA USA.
ORCID-Profile: Wonse Kim, Minjae Yoon, Jin Joo Park, Barry Greenberg
Zitieren
APA
Kim, W., Yoon, M., Kook, W., Park, J. J., & Greenberg, B. (2026). Angiotensin‐Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047533
Vancouver
Kim W, Yoon M, Kook W, Park JJ, Greenberg B. Angiotensin‐Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047533
BibTeX
@article{Kim2026,
author = {Kim, Wonse and Yoon, Minjae and Kook, Woong and Park, Jin Joo and Greenberg, Barry},
title = {Angiotensin‐Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.047533}
}
EUVIMED